Member News

Sonenberg receives honorary degree; Schekman joins Eureka science board

ASBMB Today Staff
Jan. 4, 2021

Sonenberg receives honorary doctorate

The institut national de la recherche scientifique in Quebec awarded an honorary doctorate to McGill University biochemist Nahum Sonenberg during the INRS virtual graduation ceremony in November.

Nahum Sonenberg

Sonenberg holds the Gilman Cheney chair in the department of biochemistry and the Goodman Cancer Research Centre at McGill. He earned his Ph.D. in biochemistry from the Weizmann Institute of Science in 1976 and held a Chaim Weizmann postdoctoral fellowship at the Roche Institute of Molecular Biology before joining McGill University in 1979.

The Sonenberg lab’s primary research is on the translational control of protein synthesis. His work has led a number of breakthroughs including the discovery of the mRNA 5' cap-binding protein, eIF4E, the rate-limiting component of the eukaryotic translation apparatus. eIF4E overexpression is prominent in many cancers, suggesting its utility as a tumor marker and anti-cancer drug target. The lab now works on translational control in cancer, oncolytic viruses as anti-cancer drugs, microRNA control of translation, and translational control of plasticity, learning and memory, and brain disease.

Sonenberg is a foreign associate of the National Academy of Sciences, an international member of the National Academy of Medicine and an international honorary member of the American Academy of Arts and Sciences. He has received the Killam Prize in Health Sciences, the Robert L. Noble Prize from the National Cancer Institute of Canada, the Wolfe Prize in Medicine, the Rosenstiel Award, the McLaughlin Medal of the Royal Society of Canada, the Order of Canada, and the Canada International Gairdner Award.

“Dr. Sonenberg's significant contribution to biomedical research and to advancing knowledge on a variety of diseases is undeniable,” Luc-Alain Giraldeau, INRS director general, stated in a press release. “His inspiring career, marked by major discoveries, has revolutionized today's medicine and deserves the highest honors." 

Schekman joins Eureka Therapeutics scientific board 

Randy Schekman, a professor at the University of California, Berkeley, and an investigator with the Howard Hughes Medical Institute, has joined the scientific advisory board of clinical-stage biotechnology company Eureka Therapeutics.

Randy Schekman

Schekman shared the Nobel Prize in physiology or medicine in 2013 for discoveries of machinery regulating vesicle traffic, particularly his work that began in the 1970s to characterize the yeast secretory pathway. His lab subsequently discovered a protein complex key for vesicle budding, called COPII. He is also widely known for founding the journal eLife in 2012 and for his continued calls for publishing reform and open science.

In recent years, Schekman’s lab has continued to characterize the formation and trafficking of vesicles, paying particular attention recently to extracellular vesicles that contain small RNAs and to the molecular mechanisms of autophagy.

Schekman’s honors include the Lewis S. Rosenstiel Award in basic biomedical science, the Gairdner International Award, the Eli Lilly Award in Microbiology from the American Society for Microbiology, and the Albert Lasker Award in Basic Medical Research. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.

Eureka Therapeutics was founded in San Francisco in 2006 by industry veteran Cheng Liu, who previously worked in antibody therapeutics at a company now owned by Novartis. Liu, who earned his Ph.D. at UC Berkeley, said in a press release that he and Schekman have known each other for over 20 years. Eureka Therapeutics develops T-cell therapies to target cancer cells, with particular focus on solid cancers.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
ASBMB Today Staff

This article was written by a member or members of the ASBMB Today staff.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

ASBMB members recognized as Allen investigators
Member News

ASBMB members recognized as Allen investigators

July 14, 2025

Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.

AI can be an asset, ASBMB educators say
Advice

AI can be an asset, ASBMB educators say

July 9, 2025

Pedagogy experts share how they use artificial intelligence to save time, increase accessibility and prepare students for a changing world.

ASBMB undergraduate education programs foster tomorrow’s scientific minds
Feature

ASBMB undergraduate education programs foster tomorrow’s scientific minds

July 8, 2025

Learn how the society empowers educators and the next generation of scientists through community as well as accreditation and professional development programs that support evidence-based teaching and inclusive pedagogy.

Honors for Gagna and Sundquist
Member News

Honors for Gagna and Sundquist

July 7, 2025

Claude Gagna is being honored for the diagnostic tool he developed that uses AI to streamline diagnostics. Wesley Sundquist is being honored for his role in finding that HIV’s capsid was a target for treatment.